Wyeth Hemophilia Patient Access Programs
Wyeth works to help patients with hemophilia have ongoing access to their hemophilia therapies. Through its Factor Resource Program, Wyeth provides several services to assist patients experiencing financial hardship or treatment access issues, including the Insurance-Coverage Program, the Patient Assistance Program, and the Wyeth Hemophilia Hotline (1-888-999-2349).
About Hemophilia A
Hemophilia A is a rare, inherited blood-clotting disorder characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. People with hemophilia A are deficient in a key protein -- factor VIII -- that is vital in the clotting mechanism to prevent bleeding. Most patients with hemophilia A are dependent on factor VIII replacement therapy.
Indication for XYNTHA
XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A. XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in Von Willebrand's disease.
Important Safety Information for XYNTHA
-- Anaphylaxis and severe hypersensitivity reactions are possible. Patients should be informed of the early signs of hypersensitivity reactions [including hives (rash with itching), generalized urticaria, tightness of the chest, wheezing, hypotension] and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physician if these symptoms occur.
-- Patients should be advised to contact their physician or treatment facility for further treatment and/or assessment if they experience a lack of a clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor.
-- The most common adverse re
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved